VERU
$2.41
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally.
Recent News
Veru Inc (VERU) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Veru Inc (VERU) reports progress in clinical trials and financial fortification, despite ongoing profitability hurdles.
Veru Inc. Q1 2026 Earnings Call Summary
Moby summary of Veru Inc.'s Q1 2026 earnings call
Veru (VERU) Q1 2026 Earnings Call Transcript
With me on this morning's call are Doctor Gary Barnett, our Chief Scientific Officer, Michele Greco, our Chief Financial Officer and Chief Administrative Officer, Phil Greenberg, General Counsel, and Sam Fisch, Executive Director of Investor Relations and Corporate Communications. Thank you for joining our first quarter fiscal year 2026 earnings call.
Veru Inc (VERU) Q4 2025 Earnings Call Highlights: Strategic Shifts and Financial Challenges
Veru Inc (VERU) reports significant progress in drug development and financial restructuring amid ongoing net losses and increased R&D expenses.
October 2025's Noteworthy Penny Stocks
As the U.S. stock market rebounds with major indexes like the S&P 500 hitting new all-time highs, investors are keenly observing the Federal Reserve's recent interest rate cut amidst ongoing economic uncertainties. For those willing to explore beyond established giants, penny stocks—often representing smaller or newer companies—offer intriguing possibilities despite their somewhat antiquated label. In this article, we explore three penny stocks that showcase robust financial health and...